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INTRODUCTORY PARAGRAPH
Functional redundancy shared by paralog genes may afford protection against genetic 
perturbations, but it can also result in genetic vulnerabilities due to mutual interdependency1–5. 
Here, we surveyed genome-scale shRNA and CRISPR screening data on hundreds of cancer cell 
lines and identified MAGOH and MAGOHB, core members of the splicing-dependent exon 
junction complex, as top-ranked paralog dependencies6–8. MAGOHB is the top gene dependency 
in cells with hemizygous MAGOH deletion, a pervasive genetic event that frequently occurs due to 
chromosome 1p loss. Inhibition of MAGOHB in a MAGOH-deleted context compromises 
viability by globally perturbing alternative splicing and RNA surveillance. Dependency on IPO13, 
an importin-β receptor that mediates nuclear import of the MAGOH/B-Y14 heterodimer9, is 
highly correlated to dependency on both MAGOH and MAGOHB. Both MAGOHB and IPO13 
represent dependencies in murine xenografts with hemizygous MAGOH deletion. Our results 
identify MAGOH and MAGOHB as reciprocal paralog dependencies across cancer types and 
suggest a rationale for targeting the MAGOHB-IPO13 axis in cancers with chromosome 1p 
deletion.
The systematic integration of data from genomic characterization and genetic screening of 
cancer cell lines can identify gene dependencies induced by specific somatic alterations and 
inform the development of targeted therapeutics. For example, several studies have revealed 
that inactivation of specific driver or passenger genes may confer dependency on 
functionally redundant paralogs2,3,10–13. Paralog dependencies have also emerged as 
important targets in recent genome-scale functional genomic screens4,5, underscoring the 
importance of further characterizing this class of cancer vulnerabilities.
To systematically identify paralog dependencies that may represent attractive cancer targets, 
we analyzed data from pooled, genome-scale short hairpin RNA (shRNA) screening of 501 
cancer cell lines5,14. We determined the correlation between a dependency on a gene5 and 
loss of function of its paralog across 10,287 paralog pairs (Supplementary Figure 1; 
Supplementary Note). We identified 167 genes for which dependency was significantly 
correlated to loss of a paralog (1.6% of paralog test pairs at q <0.05), including many 
previously reported paralog dependencies (e.g. ARID1B dependency with ARID1A 
inactivation10, SMARCA2 dependency with SMARCA4 inactivation11, UBC dependency 
with UBB inactivation5, and FERMT1 dependency with FERMT2 inactivation5). However, 
of these 167 paralog dependency pairs, only 7 were “symmetric”, in which dependency for 
each of the genes in the pair was significantly correlated to inactivation of its partner paralog 
(Fig. 1a-b; Supplementary Table 1). A similar analysis of data from genome-scale CRISPR 
screening of 341 cell lines15 identified 125 significant paralog dependencies (1.4% of 
paralog test pairs at q < 0.05), of which 7 pairs were symmetric (Supplementary Table 2; 
Supplementary Note). Paralog genes arise via ancestral duplication events and may 
functionally diverge over time1,16. Symmetric paralog pairs likely share complete functional 
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redundancy, making them particularly attractive targets for “collateral lethality” strategies2. 
An enrichment for RNA-splicing related genes was noted among symmetric, but not 
asymmetric, paralog pairs in the shRNA and CRISPR screening datasets (Supplementary 
Table 3), suggesting that redundant essentiality may be exploited to target splicing-related 
pathways.
One symmetric paralog pair was shared between the shRNA and CRISPR datasets: 
MAGOH-MAGOHB; a second pair, FUBP1-KHSRP, was highly significant for symmetry 
in the shRNA data and borderline significant in the CRISPR dataset (q1=0.0547) (Fig. 
1a-1b; Supplementary Figure 1; Supplementary Tables 1-2)15. We focus here on validation 
of the former pair. MAGOH and MAGOHB encode core members of the exon-junction 
complex (EJC), a multiprotein complex that is deposited on mRNAs at the time of splicing 
and that mediates diverse downstream processes including mRNA transport, stability, and 
nonsense mediated decay (NMD)6,17.
Using both shRNA and CRISPR technologies, we individually validated MAGOHB 
dependency in the setting of MAGOH loss, as well as MAGOH dependency in the setting of 
MAGOHB loss. Furthermore, in a cell line without hemizygous deletion of either paralog, 
knockdown of either MAGOH or MAGOHB individually was tolerated, but the combination 
was lethal (Supplementary Figure 2). We noted that MAGOHB dependency in the setting of 
MAGOH inactivation was particularly pronounced based on: 1) effect size (log-fold 
difference in MAGOHB dependency between MAGOH-inactivated and non-MAGOH-
inactivated cell lines) and 2) MAGOHB scoring as a robust 6σ differential dependency 
(having a dependency score in some cell lines greater than six standard deviations below its 
mean dependency score across all cell lines) in both the RNAi and CRISPR screening data. 
We therefore sought to further characterize MAGOHB dependency in the setting of 
MAGOH loss.
MAGOHB was the top differential dependency in cells with hemizygous deletion of 
MAGOH (Fig. 1c; Supplementary Tables S4-S5; Supplementary Note) and dependency on 
MAGOHB was predicted by low expression of MAGOH, consistent with the notion that 
hemizygous deletion of MAGOH leads to its decreased expression (Supplementary Figure 
3). shRNA-mediated knockdown of MAGOHB led to a decrease in cell viability and colony 
forming capacity in three MAGOH-deleted cell lines, but not in control cell lines euploid for 
MAGOH (Fig. 1d-e; Supplementary Figure 4). Ectopic expression of MAGOH in a 
MAGOH-deleted cell line fully rescued MAGOHB dependency, indicating that MAGOHB 
dependency in MAGOH-deleted cells is solely due to MAGOH loss, and consistent with 
complete functional redundancy between these paralogs8 (Fig. 1f; Supplementary Figure 4). 
CRISPR/Cas9-mediated deletion of MAGOH in a cell line with two copies of MAGOH also 
conferred MAGOHB dependency (Supplementary Figures S5-S6).
To assess the clinical contexts in which these dependencies might be exploited, we next 
surveyed the frequency of MAGOH and MAGOHB loss in tumor cohorts from the Cancer 
Genome Atlas (TCGA). We observed pervasive hemizygous MAGOH loss across tumor 
types (frequency of 21% (1675/8009) in the entire TCGA dataset, and >50% in multiple 
tumor types). Moreover, MAGOH deletion most frequently occurs as a result of arm level 
Viswanathan et al. Page 3





















deletion of chromosome 1p across human tumors (Fig. 1g; Supplementary Table 6). We 
confirmed that chromosome 1p-deletion status correlates with MAGOHB dependency in the 
genome-scale CRISPR screening data (Supplementary Figure 7). In the context of 
neuroblastoma – where 1p deletion is a hallmark event in a subset of tumors18 – MAGOHB 
knockdown was lethal in a 1p-deleted, but not a 1p-neutral, cell line (Supplementary Figure 
7). MAGOHB is located on chromosome 12p, an arm also recurrently lost across tumor 
types, albeit with markedly lower frequency than chromosome 1p (Supplementary Figure 8). 
Analysis of genome-scale CRISPR screening data confirmed a reciprocal dependency on 
MAGOH in the setting of chromosome 12p deletion. Interestingly, we also observed mutual 
exclusivity between chromosome 1p and chromosome 12p co-deletion in many tumor types, 
suggesting that concurrent loss of both MAGOH and MAGOHB may be poorly tolerated 
(Supplementary Figure 8). We conclude that MAGOH and MAGOHB represent potential 
vulnerabilities in large, genetically defined, subsets of tumors.
MAGOH and MAGOHB constitute core components of the EJC8; EJC deposition at exon-
exon junctions allows transcripts containing premature termination codons (PTCs) to be 
identified and targeted for degradation via NMD6,17. We therefore hypothesized that 
MAGOHB inhibition in the setting of decreased MAGOH dosage may compromise cell 
viability by perturbing RNA splicing and RNA surveillance. To evaluate the global 
transcriptomic consequences of MAGOHB inhibition, we performed RNA sequencing on 
hemizygous MAGOH-deleted ChagoK1 cells in the presence or absence of MAGOHB 
knockdown, with or without ectopic re-expression of MAGOH. We observed an increased 
expression of NMD biotype transcripts upon MAGOHB knockdown in ChagoK1 cells (Fig. 
2a, left). In contrast, MAGOHB knockdown in MAGOH-reconstituted ChagoK1 cells was 
well-tolerated without a notable shift in NMD biotype transcript distribution (Fig. 2a, right). 
We next sought to determine whether the upregulation of NMD isoforms upon MAGOHB 
knockdown in ChagoK1 cells was occurring at the expense of other transcript biotypes. 
Among genes that had significantly upregulated NMD isoform(s) upon MAGOHB 
knockdown, we observed a significant proportional decrease in coding isoform expression in 
ChagoK1 cells but not MAGOH-reconstituted ChagoK1 cells (Fig. 2b, compare left and 
right). To investigate whether particular splice event classes were driving this redistribution 
of isoform types, we quantified the proportion of differentially spliced events of each class 
that were more common in either the absence (Fig. 2c, red) or presence (Fig. 2c, blue) of 
MAGOHB knockdown in either ChagoK1 cells or MAGOH-reconstituted ChagoK1 cells. 
As compared with MAGOHB knockdown in MAGOH-reconstituted ChagoK1 cells, 
MAGOHB knockdown in ChagoK1 cells resulted in reduced cassette exon inclusion and 
increased intron retention (Fig. 2c). Therefore, many global transcriptomic effects of 
MAGOH/B insufficiency appear attributable to alterations in these two splice event types, 
indicative of a defect in exon definition/recognition.
We identified 22 instances in which there was both a significant absolute upregulation of an 
NMD isoform (beta > 1 in differential expression analysis using Kallisto19) and 
corresponding downregulation of at least one protein coding isoform (beta < −1) 
(Supplementary Table 7). These genes were significantly enriched for pathways involved in 
mRNA splicing and mRNA processing (Supplementary Table 8; Fig. 2d). Intriguingly, 
among the seven splicing-related genes driving this enrichment were four genes (SRSF2, 
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SRSF7, HNRNPDL, HNRNPH1) reported to auto-regulate their expression via alternative 
splicing-nonsense mediated decay (AS-NMD) loops20,21. Such AS-NMD loops, many of 
which are in splicing-related genes, involve ultraconserved, regulated alternative splicing 
events that induce NMD-substrates, thus maintaining homeostatic control of gene 
expression20,21. We observed perturbations in isoform distributions of HNRNPDL and other 
splicing-related genes upon MAGOHB knockdown in ChagoK1 cells, but not in MAGOH-
reconstituted ChagoK1 cells (Fig. 2e; Supplementary Figures 9–10; Supplementary Note). 
Altered RNA isoform abundance accompanied by changes in the levels of functional 
protein, either via disruption of AS-NMD loops or through other mechanisms, could have 
deleterious direct and indirect consequences on cellular splicing.
Given these transcriptomic consequences of MAGOH/MAGOHB insufficiency, we next 
sought to determine whether MAGOH loss unveils a broader dependency on splicing/NMD-
related complexes. We performed immunoprecipitation and mass spectrometry to identify 
MAGOH- and MAGOHB-associated binding partners and found that these interactors, 
which include many splicing-related genes, were enriched for gene dependencies correlated 
to both MAGOH and MAGOHB dependencies. However, these dependencies were weaker 
than the reciprocal MAGOH/B paralog dependencies driven by redundant essentiality 
(Supplementary Figure 11; Supplementary Tables 9-11; Supplementary Note).
MAGOH and MAGOHB share near-identity at the protein level and functional and 
crystallographic studies do not reveal domains easily amenable to targeting by small 
molecules22. To identify other more tractable targets that might indirectly affect MAGOH/
MAGOHB function, we interrogated the genome scale shRNA screening data for gene 
dependencies highly correlated to either MAGOH or MAGOHB dependency. Strikingly, 
IPO13 emerged as the top, outlier correlated gene dependency to both MAGOH and 
MAGOHB (Fig. 3a; Supplementary Table 12). IPO13 is a bidirectional karyopherin 
responsible for nuclear import of the MAGOH/B-Y14 heterodimer, a function critical for 
recycling of the EJC; it is also located on chromosome 1p in proximity to MAGOH, and the 
two genes are frequently co-deleted17 (Fig. 3b; Supplementary Table 13).
We observed a selective IPO13 dependency in MAGOH-deleted cell lines compared to non-
deleted cell lines (Fig. 3c) and found that dependency on IPO13 in MAGOH-deleted H460 
and H1437 cells was partially attenuated by MAGOH re-expression (Fig. 3d; Supplementary 
Figure 12; Supplementary Note). Knockdown of IPO13 in MAGOH-deleted cells led to 
cytoplasmic accumulation of MAGOH/MAGOHB and subsequent upregulation of the 
NMD-substrates SC1.6 and SC1.7, an effect that was rescued by MAGOH re-expression 
(Fig. 3e; Supplementary Figure 13). This suggests that IPO13 dependency in MAGOH- and 
MAGOHB-deleted cells is mediated in part by defective shuttling of MAGOH/B, resulting 
in mis-splicing and impaired RNA surveillance. Haploinsufficiency of IPO13, as occurs 
when MAGOH and IPO13 are co-deleted, may also contribute to IPO13 dependency in 
some contexts.
Finally, we sought to validate MAGOHB as a target in vivo. We formed xenografts from 
H1437 cells (which carry a hemizygous deletion in MAGOH) transduced with a lentiviral 
vector encoding a doxycycline-inducible shRNA against MAGOHB. Xenograft growth was 
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significantly impaired upon MAGOHB knockdown. (Fig. 4a-b). To next assess this 
dependency using a more therapeutically tractable system, we used tumor-penetrating 
nanocomplexes (TPNCs) capable of targeted delivery of siRNAs to the cytosol of tumor 
cells23. The TPNCs were decorated with the tumor-homing peptide iRGD, which allows for 
targeted delivery of siRNAs to tumor cells expressing surface NRP1/αvβ3; both receptors 
are expressed on H1437 cells (Fig 4c). H1437 xenograft growth was significantly impaired 
upon intra-tumoral injection of si-MAGOHB and si-IPO13-containing TPNCs, but not 
TPNCs containing control siRNA against GFP (Fig. 4d-e; Supplementary Figure 14). This 
finding was confirmed using a second TPNC-system using a distinct tumor-homing peptide, 
Lyp-1 (Supplementary Figure 14). Additionally, tumors treated with si-MAGOHB-
containing TPNCs displayed higher levels of cleaved caspase-3, indicating that targeting 
MAGOHB in a MAGOH-hemizygous context triggers apoptotic cell death (Supplementary 
Figure 14). Thus, MAGOHB and IPO13 represent potential in vivo targets in a MAGOH-
deleted context, and this paralog vulnerability may be exploited by antisense or RNAi-based 
approaches.
Hemizygous chromosome arm loss is one of the commonest features of cancer genomes24,25 
and rational therapeutic targeting of this class of somatic events would therefore be 
attractive. Prior studies have identified several candidate targets unmasked by genomic 
loss4,5,26,27. Here, we integrate genomic characterization and genome-scale functional 
screening of cancer cell lines to systematically extend such studies. We identify a set of 
robust paralog dependencies that may provide the foundation for future target validation 
efforts and show that hemizygous loss of the MAGOH gene on chromosome 1p confers 
novel vulnerabilities on MAGOHB and IPO13, perhaps due to decreased nuclear reserve of 
MAGOH/MAGOHB (Supplementary Figure 15). Insufficient MAGOH/MAGOHB dosage 
perturbs splicing and RNA surveillance and adds to growing evidence implicating splicing 
as a cancer dependency27–29. Therapeutic approaches to targeting MAGOH-deleted cells 
may involve either direct MAGOHB transcript suppression (such as through antisense/RNAi 
approaches), targeted MAGOHB protein degradation, or indirect suppression of MAGOH/
MAGOHB activity via inhibition of IPO13. Antisense/RNAi-based approaches may be well 
suited to the exploitation of paralog dependencies, as they may allow for selective targeting 
of paralogs that show greater variability on the nucleotide level than on the protein level. 
Targeted protein degradation approaches have also recently proven to be a promising means 
to target conventionally “undruggable” genes30–33, including RNA splicing factors34. In the 
case of IPO13 dependency, small molecule inhibitors of other importin family members 
have been described, raising the possibility that IPO13 can be selectively targeted using a 
similar strategy35–37. As hemizygous loss of chromosome 1p is extremely common across 
multiple tumor types, these or other approaches to targeting this pathway may have future 
biomarker-driven therapeutic applications. More broadly, our work can be generalized to 
cancers with other chromosome arm deletions and underscores the power of intersecting 
comprehensive molecular characterization and functional genomic studies of cancer cell 
lines.
Viswanathan et al. Page 6























Cell line stocks used for validation experiments were obtained either from the Cancer Cell 
Line Encyclopedia repository at the Broad Institute or from M.M’s laboratory, with original 
sources being either the American Type Culture Collection, the European Collection of 
Authenticated Cell Cultures, the Health Science Research Resources Bank, Korean Cell 
Line Bank or academic laboratories. Cell line identity was verified by either STR profiling 
or Affymetrix SNP profiling. Cells were cultured in media specified by the source 
repository, supplemented with 100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM L-
glutamine, and 100 μg/mL Normocin (Invivogen). Mycoplasma testing was performed in 
source repository prior to creation of frozen stocks and repeated periodically if lines were 
persistently maintained in culture.
Lentiviral constructs and transduction of cell lines
For overexpression experiments, ORFs were expressed from within the pLX304-Blast-V5 
vector38 (Addgene #25890, Blasticidin resistance) using pLX304-eGFP as an 
overexpression negative control. Ectopic expression of untagged MAGOH was performed 
either using pLX304 (with stop codon introduced prior to V5 tag) or Gateway-compatible, 
Hygromycin-resistant, doxycycline-inducible overexpression vector with cDNA expression 
driven from Tet-regulated CMV promoter, created by modification of prior similar 
vectors39,40. MAGOH-reconstitution experiments were performed with V5-tagged MAGOH 
with the exception of those shown in Supplemental Figure 4e, which were performed using 
an untagged construct. For shRNA experiments, constitutive shRNAs were expressed from 
the pLKO.1 vector41 (Addgene # 10878, Puromycin resistance) using an shRNA targeting 
GFP (shGFP) as a negative control. shRNA constructs were obtained from the RNAi 
Consortium shRNA collection (see URLs) Inducible shRNAs were cloned into a Gateway-
compatible doxycycline-inducible lentiviral shRNA expression system (G418 resistance), as 
described39. sgRNAs were cloned into lentiCRISPRv2 (Addgene #52961) as described (see 
URLs). shRNA and sgRNA target sequences are listed in Supplementary Table 14.
Lentivirus was produced in HEK293T cells as per the “low throughput viral production” 
protocol on the RNAi Consortium Portal (see URLs). Cells were transduced with lentivirus 
by spin-infection (2250 rpm for 30 minutes) in the presence of 8 μg/ml polybrene, followed 
by antibiotic selection beginning 24 hours thereafter. Following completion of antibiotic 
selection, cells were seeded for downstream assays as described.
URLs
Broad RNAi Consortium, http://www.broadinstitute.org/rnai/public
LentiCRISPRv2 Cloning Protocol, http://genome-engineering.org/gecko/wp-content/uploads/2013/12/lentiCRISPRv2-and-lentiGuide-
oligo-cloning-protocol.pdf
Lentiviral Production Protocol, http://portals.broadinstitute.org/gpp/public/resources/protocols
Bash script for expectation maximization algorithm, http://www.lagelab.org/resources
HUGO Gene Nomenclature Committee, http://www.genenames.org/cgi-bin/genefamilies
rMATS2Sashimiplot, https://github.com/Xinglab/rmats2sashimiplot
ENSEMBL Biomart, http://www.ensembl.org/biomart DepMap Portal, http://depmap.org
MassIVE, http://massive.ucsd.edu
NCBI GEO, https://www.ncbi.nlm.nih.gov/geo/
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Gene knockdown or knockout was confirmed by quantitative RT-PCR for MAGOH/B as the 
paralogs cannot be distinguished on Western blotting. Gene overexpression was confirmed 
by Western blotting.
Generation of MAGOH-knockout cell lines
For generation of MAGOH-knockout cell lines, Heya8 cells were transiently transfected 
with either a non-targeting guide (sgGFP) or MAGOH sgRNA expressed from within 
plentiCRISPRv2. Following 72 hours of selection with puromycin, the bulk resistant 
population was sorted at single cell density into 96 well plates using a MoFlo Astrios Cell 
Sorter (Beckman Coulter). Clonal cell lines were expanded and assessed for MAGOH 
knockout by quantitative PCR.
Western blotting
Whole-cell extracts for immunoblotting were prepared by incubating cells on ice in RIPA 
lysis buffer (ThermoFisher Scientific) plus protease inhibitors (cOmplete, Mini, EDTA-free, 
Roche) for 20 minutes. Following centrifugation (>16,000 r.c.f. for 15 minutes), protein 
lysates were quantitated using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific). 
Lysates were separated by SDS-PAGE and transferred to nitrocellulose membranes using the 
iBlot2 system (Life Technologies). Two-color immunoblotting was performed using the LI-
COR platform (LI-COR Biosciences) with IRDye 800CW and IRDye680RD secondary 
antibodies (mouse, IRDye 680LT Donkey anti-Mouse IgG (925–68022) used at 1:10000; 
rabbit, IRDye 800CW Goat anti-Rabbit IgG (926–32211) used at 1:10000). Imaging was 
performed on an Odyssey CLx Infrared Imaging System. Loading control and experimental 
protein were probed on the same membrane in all cases. For clarity, loading control is 
cropped and shown below experimental condition in all panels regardless of relative 
molecular weights of the two proteins.
Primary antibodies and dilutions used were as follows. HNRNPDL: Thermo Fisher 
Scientific (PA5–35896), 1:2000. Vinculin: Sigma-Aldrich (V9264), 1:4000. MAGOH: Santa 
Cruz Biotechnology (sc-271365), 1:250 or Abcam (ab38768) (1:500). Actin: Cell Signaling 
Technology (D6A8, mAb #8457), 1:1000 or Cell Signaling Technology (8H10D10, mAb 
#3700), 1:2000. PSPC1, Santa Cruz Biotechnology (sc-374181), 1:100. HNRNPH1, Bethyl 
Laboratories (A300–511A), 1:1000.
Quantitative PCR
RNA isolation was performed using the RNeasy Mini Kit (Qiagen). cDNA preparation was 
performed using Superscript III cDNA synthesis kit (Thermo Fisher Scientific). PCR 
reactions were prepared using Taqman Gene Expression Mastermix (Thermo Fisher 
Scientific) and PrimeTime qPCR probe-based assays (IDT) using HPRT1 as an internal 
normalization control. Taqman assay ID catalog numbers are as provided in Table S3. Real-
time quantitative PCR was performed on a QuantStudio 6 Flex Real-Time PCR System 
(Applied Biosystems) and results were quantitated using the ΔΔCt method. For 
quantification of SC35 NMD substrates, quantitative PCR was performed using a Power 
SYBR Green PCR Master Mix (Thermo Fisher Scientific) and primer sequences for SC1.6 
and SC1.7 as described8 using β-actin as an internal normalization control.
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Cell Viability and Colony Formation Assays
For cell viability assays, cells were seeded in 96-well plates in 100 μl of medium after 
lentiviral transduction and completion of antibiotic selection. For inducible hairpin 
experiments, equal numbers of cells were seeded for both “-Dox” and “+Dox” conditions 
and medium was supplemented with 100 ng/ml doxycycline in the “+Dox” condition. Cells 
were seeded in 96 well plate format (range 1000–8000 per well, depending on the cell line). 
At 7–10 days after cell seeding, cell viability was assessed using the Cell Titer-Glo 
luminescent cell viability assay (Promega) using either an EnVision Multilabel Reader 
(Perkin Elmer) or a Spectramax M5 plate reader (Molecular Devices).
For colony formation assays, cells were seeded in 12-well plates at a density of 2000–8000 
cells per well after lentiviral transduction and completion of antibiotic selection. Cells were 
cultured for 10–20 days. Colonies were fixed in 4% formaldehyde and stained with 0.5% 
crystal violet. Cells were photographed using a Leica microscope. Colonies were then 
destained using 10% acetic acid and crystal violet staining was quantified by measuring 
absorbance at 595 nm using a Spectramax M5 instrument (Molecular Devices).
Immunofluorescence
For immunofluorescence assays, 200,000 cells were plated on SecureSlip silicone supported 
coverglasses (Sigma Aldrich) in 6-well plates that had been pre-coated for 60 minutes with 
0.01 mg/mL human fibronectin (Calbiochem) in PBS. The following day, cells were fixed in 
4% paraformaldehyde (PFA) diluted in PBS for 15 minutes at room temperature. Cells were 
permeabilized with 0.2% Triton X-100 in PBS for 10 minutes. Blocking was performed in 
2.5% normal goat serum blocking solution (Vector Laboratories). Cells were incubated in 
primary MAGOH/MAGOHB antibody (Abcam, ab38768, rabbit, 1:200) for 1 hr at RT. A 
Cy-3 conjugated anti-rabbit secondary (Abcam, ab97075, 1:200) and DAPI (1:1000, Life 
Technologies) were then used for 1 hr at RT. Cells were mounted and imaged on an Axio 
Observer fluorescent microscope (Zeiss) using AxioVision software (Zeiss). Nuclear/
Cytoplasmic ratio was quantified by Image J. Nuclear outlines were determined based on 
DAPI signal. Cytoplasmic signal was defined as signal in the whole cell minus signal within 
the nuclear area.
Mouse Experiments
Studies involving mice were approved by the MIT Committee on Animal Care. Mouse strain 
used as NCR-nude (Charles River Laboratories), female, 4–5 weeks of age. For inducible 
shRNA xenograft experiments, NCR-nude mice were subcutaneously injected into bilateral 
flanks with 3.5 × 106 H1437 cells transduced with lentivirus expressing a doxycycline-
inducible shRNA against MAGOHB (MAGOHB-sh2). Cells were resuspended in 100 μL of 
30% matrigel in PBS. At 7 days post-injection, after tumor implantation, mice were 
randomized to match tumor size between two groups, and one group was started on a diet 
containing 200 mg doxycycline/kg (Bio-Serv, Flemington, NJ). Tumor volumes were 
measured twice weekly using a digital caliper.
For tumor-penetrating nanocomplex (TPNC) experiments, xenografts were produced as 
above using 2.5 × 106 cells per tumor. TPNCs were prepared by complexing siRNA with 
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tandem peptide at a 1:20 (LyP1) or 1:15(iRGD) molar ratio (siRNA:peptide) in water. For 
intratumoral injections, 0.2nmol siRNA were injected every 1–2 days in 20uL of TPNC 
solution. Myr-TP-LyP1 (myr-GWTLNSAGYLLGKINLKALAALAKKILGGGG-
K(5TAMRA)-CGNKRTRGC (C-C bridge)) and Palm-TP-iRGD (palm-
GWTLNSAGYLLGKINLKALAALAKKILGGGG-CRGDKGPDC (C-C bridge)) were 
synthesized by CPC Scientific. siRNAs were purchased from GE Dharmacon. MAGOHB 
siRNA target sequence was as in MAGOHB-sh2. IPO13 siRNA target sequence as in 
IPO13-sh3 (see Supplementary Table 14 for sequences). Surface expression of p32 or 
NRP-1 were evaluated by flow cytometry using anti-p32 antibody at 1:1000 dilution 
(AB2991, EMD Millipore) or anti-alpha V beta 3-PE conjugated antibody at 1:100 dilution 
(FAB3050P, R&D Systems) or anti-Neuropilin1 antibody at 1:1000 dilution (AB9600, 
Millipore), or matched isotype control, and visualized with AlexaFluor 647-labeled 
secondary antibody (p32 and NRP-1) or conjugated PE (ɑvβ3).
Immunostaining was performed as previously described42. Briefly, six tumors from each 
condition (randomly selected) were extracted and fixed in 10% formalin overnight and 
stored at 4˚C before being embedded in paraffin, sectioned, and stained. Tumor sections 
were stained with primary antibody to Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb 
#9664 (Cell Signaling Technology, 1:1000) and HRP-conjugated anti-rabbit secondary 
antibody (RABBIT-ON-RODENT HRP-POLYMER from BioCare Medical, Cat #RMR622) 
on a ThermoScientific IHC Autostainer 360 and visualized with DAB chromogen. For 
cleaved caspase-3 quantification, fractional of cross-sectional area staining positive for 
cleaved caspase-3 was quantified in the six randomly selected tumors from each group that 
were stained, using ImageJ.
Immunoprecipitation and Mass Spectrometry
Immunoprecipitation.—For immunoprecipitation experiments, 293T cells were either 
untransduced (control) or transduced with pLX304-Blast-V5 (Addgene #25890) expressing 
MAGOH-V5 or MAGOHB-V5. Following antibiotic selection to derive stably transduced 
cell populations, immunoprecipitation was carried out using the Pierce Class Magnetic IP 
Kit (#88804) and anti-V5 magnetic beads (MBLI #M167–11) using a starting amount of 2 
mg protein and 50 μl beads. Lysis buffer was pH 7.4, 0.025M Tris, 0.15M NaCl, 0.001M 
EDTA, 1% NP40, 5% glycerol. Immunoprecipitation was carried out overnight at 4oC. 
Samples were washed twice in sample buffer, followed by twice in PBS prior to mass 
spectrometry. Efficient immunoprecipitation was confirmed by western blotting prior to 
proceeding with mass spectrometry.
Protein digestion and labeling with TMT isobaric mass tags.—The beads from 
immunopurification were washed once with IP lysis buffer, then three times with PBS, the 
four different lysates of each replicate were resuspended in 90 uL digestion buffer (2M Urea, 
50 mM Tris HCl), 2 ug of sequencing grade trypsin added, 1 hour shaking at 700rpm. The 
supernatant was removed and placed in a fresh tube. The beads were then washed twice with 
50 uL digestion buffer and combined with the supernatant. The combined supernatants were 
reduced (2 uL 500 mM DTT, 30 minutes, RT), alkylated (4 uL 500 mM IAA, 45 minutes, 
Viswanathan et al. Page 10





















dark) and a longer overnight digestion performed: 2 ug (4 uL) trypsin, shake o/n, The 
samples were then quenched with 20 uL 10% FA and desalted on 10 mg Oasis cartridges.
Desalted peptides were labeled with TMT6 reagents lot QD218427 (Thermo Fisher 
Scientific) according to the following: 126, NoBaitCntlRep1; 127, NoBaitCntlRep2; 128, 
MAGOHRep1; 129, MAGOHRep2; 130, MAGOHBRep1; 131, MAGOHBRep2. Peptides 
were dissolved in 25uL of fresh 100mM HEPES buffer. The labeling reagent was 
resuspended in 42 ul of acetonitrile and 10 ul added to each sample as described below. 
After 1 h incubation the reaction was stopped with 8uL of 5mM Hydroxylamine.
Protein identification with nanoLC–MS system.—Reconstituted peptides were 
separated on an online nanoflow EASY-nLC 1000 UHPLC system (Thermo Fisher 
Scientific) and analyzed on a benchtop Orbitrap Q Exactive plus mass spectrometer (Thermo 
Fisher Scientific). The peptide samples were injected onto a capillary column (Picofrit with 
10 μm tip opening / 75 μm diameter, New Objective, PF360–75-10-N-5) packed in-house 
with 20 cm C18 silica material (1.9 μm ReproSil-Pur C18-AQ medium, Dr. Maisch GmbH) 
and heated to 50 °C in column heater sleeves (Phoenix-ST) to reduce backpressure during 
UHPLC separation. Injected peptides were separated at a flow rate of 200 nL/min with a 
linear 230 min gradient from 100% solvent A (3% acetonitrile, 0.1% formic acid) to 30% 
solvent B (90% acetonitrile, 0.1% formic acid), followed by a linear 9 min gradient from 
30% solvent B to 60% solvent B and a 1 min ramp to 90%B. Each sample was run for 260 
min, including sample loading and column equilibration times. The Q Exactive instrument 
was operated in the data-dependent mode acquiring HCD MS/MS scans (R=17,500) after 
each MS1 scan (R=70,000) on the 12 top most abundant ions using an MS1 ion target of 3× 
106 ions and an MS2 target of 5×104 ions. The maximum ion time utilized for the MS/MS 
scans was 120 ms; the HCD-normalized collision energy was set to 27; the dynamic 
exclusion time was set to 20s, and the peptide match and isotope exclusion functions were 
enabled.
Database search and data processing.—All mass spectra were processed using the 
Spectrum Mill software package v6.0 pre-release (Agilent Technologies) which includes 
modules developed by us for TMT6 -based quantification. For peptide identification MS/MS 
spectra were searched against human Uniprot database to which a set of common laboratory 
contaminant proteins was appended. Search parameters included: ESI-QEXACTIVE-HCD 
scoring parameters, trypsin enzyme specificity with a maximum of two missed cleavages, 
40% minimum matched peak intensity, +/− 20 ppm precursor mass tolerance, +/− 20 ppm 
product mass tolerance, and carbamidomethylation of cysteines and TMT6 labeling of 
lysines and peptide n-termini as fixed modifications. Allowed variable modifications were 
oxidation of methionine, N-terminal acetylation, Pyroglutamic acid (N-termQ),Deamidated 
(N),Pyro Carbamidomethyl Cys (N-termC),with a precursor MH+ shift range of −18 to 64 
Da. Identities interpreted for individual spectra were automatically designated as valid by 
optimizing score and delta rank1-rank2 score thresholds separately for each precursor charge 
state in each LC-MS/MS while allowing a maximum target-decoy-based false-discovery rate 
(FDR) of 1.0% at the spectrum level.
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Analysis.—The expectation maximization algorithm43 was applied to the results of the 
peptide report (the in-house written bash script is available on the Lage Lab Resources Site 
(see URLs) and the peptide report can be found in the supplementary materials). The list of 
most likely observed proteins was generated for each channel of the MS experiment based 
on Swiss-Prot and TrEMBLE databases of protein sequences44. Next, ratios of intensities 
between channels were calculated and median normalized. Resulting data were analyzed and 
visualized using R. Statistical analyses were performed via moderated t-test from R package 
limma45 to estimate p values for each protein and the false discovery rate corrections (FDR) 
were applied to account for multiple hypothesis testing. Plots were created using in-house 
written R scripts and gplot246. RNA-binding and S ribosomal protein families were taken 
from HUGO Gene Nomenclature Committee (see URLs). Proteins previously reported to be 
EJC/NMD complex members7 were annotated as such.
Analysis of Cancer Cell Lines
Copy Number Analysis—Details regarding arm-level copy number calling are as 
described in Taylor et al. (2018)47. Briefly, to determine arm-level events (i.e. 1p or 12p 
deletion status) in TCGA and CCLE samples, the ABSOLUTE algorithm48 was used to 
determine the likeliest ploidy and absolute total copy number of each genomic segment. 
Segments were called as amplified, deleted or copy neutral based on copy number with 
reference to integer-rounded ploidy. Arm or chromosome level amplification/deletion status 
was then determined from segment data as described in Taylor et al. (2018)47.CCLE cell 
lines were fit to clusters within their corresponding TCGA tumor type to generate cell line-
specific, arm-specific calls49. For CCLE data, ABSOLUTE algorithm was run on the CCLE 
Affymetrix SNP6.0 array data as previously reported50. For analysis of arm-level and focal 
copy number event in TCGA data sets, 1p deletion status was determined as described 
above. Hemizygous MAGOH deletion was defined as the loss of one or more copies of the 
MAGOH gene (e.g. ploidy – MAGOH copy number >= 1) using rounded tumor ploidy and 
MAOGH copy number calculated from the ABSOLUTE algorithm.
Genome-scale shRNA and CRISPR Screening Data Analysis—Genome-wide 
shRNA screening on 501 cell lines was performed as described5. The DEMETER method, 
which summarizes multiple shRNAs targeting a gene into a gene-level dependency score, 
was used to quantify gene dependency in 17,098 unique genes5. The differential dependency 
set of 6,305 genes, and the 6σ dependency set of 769 genes, as defined previously5, were 
used for all downstream analysis. These sets represent the genes with the most significant 
differential dependency across cell lines and were selected based on the following criteria: 1) 
for each gene, there is at least one cell line with a dependency score that is two (differential 
set) or six (6σ set) standard deviations from the mean of scores from all genes and all cell 
lines, and 2) expression of the gene in the most dependent cell line is above –2 log 2 RPKM.
To identify synthetic lethal relationships linked to loss of a paralog, a query was performed 
for each of 17,670 genes using EnsemblCompara51 via the R interface to BioMart52 to 
obtain a list of paralogs and their pairwise sequence identity. Pearson correlations of 
RNAseq expression values between genes in each paralog pair indicate that co-expression is 
limited until DNA sequence identity exceeds 25% (Supplementary Figure 1). To increase the 
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likelihood that the gene pairs function redundantly, pairs with less than 25% sequence 
identity were removed. An additional 35 genes were removed for having duplicate 
DEMETER scores (caused by non-unique hairpins), resulting in 3,403 genes in the 
DEMETER dataset with at least one paralog. Differential dependency for each of these 
genes was tested by grouping cell lines based on loss of the gene’s paralogs and performing 
a two-class comparison of the DEMETER scores using empirical Bayes moderated t-
statistics implemented by the R package ‘limma’45. The binary classification of paralog loss 
used to group the cell lines was determined by a logic combination of the RNAseq gene 
expression (GE), protein abundance (RPPA), relative copy number (CN), methylation 
fraction (RRBS) and mutation status (WES,WGS,RNAseq). The GE, RPPA, CN, and RRBS 
datasets are z-scored per gene so loss of a gene is defined as having a 6σ decrease in GE or 
RPPA, or no GE at all (less than −3 log2 TPM), 2σ decrease in CN, 6σ increase in RRBS, or 
a deleterious mutation (predicted by frameshift indel or nonsense SNV). Genes are labeled 
‘symmetric’ if loss of either gene in a pair is significantly associated with a selective 
dependency on its respective paralog gene with FDR < .05.
The synthetic lethal paralog analysis was repeated using the Achilles CRISPR dataset15 
consisting of 341 whole genome CRISPR/cas9 knockout screens corrected for copy number 
effects (one cell line, PK59, was removed from the prior set of 342 as it failed 
fingerprinting). Genes with variance in essentiality below .01 across the 341 cell lines were 
removed to reduce false positives, leaving 6,535 genes for paralog dependency analysis. The 
definition of gene loss as well as method for determining significance of differential 
dependency among each paralog pair is identical to the analysis using DEMETER data.
For analysis of gene dependencies correlated with MAGOH deletion (Fig 1), the PARIS 
algorithm was run as a GenePattern module (https://www.broadinstitute.org/achilles/
resources). MAGOH-deletion status was determined by the ABSOLUTE algorithm48 as 
described above. Cell lines for which MAGOH absolute copy number was less than the cell 
line’s ploidy were considered deleted. Based on available ABSOLUTE calls, 191 lines were 
considered deleted and 807 lines were considered non-deleted. In total, both absolute copy 
number and filtered DEMETER gene-score data was available for 445 overlap cell lines.
For geneset enrichment analysis on gene dependencies correlated with MAGOH deletion, 
the PARIS algorithm was first run using continuous copy number data on CCLE cell lines 
generated using SNP arrays, as previously reported50 to generate a ranked list of gene 
dependencies correlated with MAGOH copy number. RNMI metric score for each gene was 
then used as input for preranked geneset enrichment analysis53, which was run as a 





For analysis of correlated gene dependency profiles, Pearson correlations of DEMETER 
gene dependency scores were computed across cell lines (N=501) for all pairs of genes that 
share overlap in cell lines (N=6,300). Correlation coefficients were converted to standard 
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scores across the full correlation matrix before evaluating the specific MAGOH and 
MAGOHB correlation profiles.
RNA-Seq Analysis—RNA-Seq libraries were prepared using the Illumina strand-specific 
mRNA seq library prep kit (Illumina) followed by paired-end 75 bp sequencing on a 
NextSeq (>400M reads per run; >33M reads/sample). Transcript levels were quantified with 
kallisto19 (version 0.43.0, options: –rf-stranded, –b 30) using the GRCh38 transcriptome 
(ENSEMBL cDNA, release 87)54. Differential expression analysis was performed with 
sleuth55 (version 0.28.1). Differential expression was quantified based on the “beta” value, a 
bias estimator used by kallisto19 analogous to fold-change. Significant upregulation cut-offs 
were b>1, q<0.01; downregulation b < −1. Gene Ontology (GO)56 term enrichment analysis 
was carried out using PANTHER57. Overrepresentation Test (release 20160715) using the 
GO database (release 2017–01-26), accessible via the GO website (www.geneontology.org, 
last accessed 2017–01-31). Transcript biotypes were obtained from the ENSEMBL database 
(release 87)54. For analysis of differential alternative splicing events, reads were aligned 
with HiSat2 (v2.0.4, --rna-strandness RF option)58 using the prebuilt index Ensembl 
GRCh38 (genome_tran), and splicing events were quantified using rMATS v3.2.559. For 
increased stringency, rMATS output was filtered based on read support (sum of inclusion/
exclusion reads >= 10 in both samples), FDR (<0.05), and inclusion level difference (|ILD|
>0.1). Sashimi plots were plotted using rMats2Sashimiplot (see URLs) in grouping mode.
For estimation of protein-level effects from RNA-Seq data, peptide sequences for each 
transcript were obtained using ENSEMBL biomart (see URLs), accessed through the R 
package biomaRt (version 2.26.1) 52,60. For each gene, expected peptide expression was 
then estimated by summing over TPM values for all transcripts that encode peptides of the 
same length.
REVEALER analysis—To identify associations between MAGOH/B dependency and 
copy number/expression features of EJC/splicing related genes, MAGOH or MAGOHB 
dependency scores across screened cell lines5 were correlated to copy number or expression 
features50 in EJC/splicing-related genes using the previously described method based on 
estimating the Information Coefficient61. For radial plots, the top scoring 50 features (for 
copy number) or top scoring 16 features (for expression) were plotted. A list of EJC/
splicing-related genes used for this analysis was compiled by combining EJC/NMD genes in 
MSigDB (Reactome geneset #M1067) and splicing factors described to be implicated in 
oncogenesis62.
Statistics
No statistical methods were used to pre-determine sample size. Investigators were not 
blinded to allocation for experiments. Statistical tests applied, p-values, and sample size are 
as listed in figure captions. For in vitro experiments, number of biologically independent 
replicates is as listed in figure captions. When two-sample Student’s t-tests were applied to 
assess significance of experimental data, unequal variance parameter was used and p-values 
were calculated using Microsoft Excel (function t.test; heteroscedastic). Other statistical 
tests were performed using R (v. 3.4.1) or GraphPad Prism 7 software.
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Figure 1. Hemizygous MAGOH deletion confers MAGOHB dependency.
(a) Analysis of paralog dependencies in genome-scale screening of cancer cell lines 
(shRNA, 501 lines; CRISPR-Cas9, 341 lines).
(b) q-value:q-value plot showing significance of pairwise correlation between a gene’s 
dependency score and inactivation of its paralog. q-value 1, significance for dependency on 
the paralog labeled first with inactivation of the paralog labeled second. q-value 2, 
significance for dependency on the paralog labeled second with inactivation of the paralog 
labeled first. “Symmetric” paralogs are in upper right quadrant (q1 < 0.05 and q2 < 0.05). 
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Plots show n=1970 paralog pairs for shRNA data and n=1593 pairs for CRISPR data. One-
sided p-value from two class comparison was calculated via moderated t-statistic and 
adjusted for multiple comparisons using the Benjamini-Hochberg false-discovery rate 
(FDR).
(c) Probability Analysis by Ranked Information Score (PARIS) analysis to identify gene 
dependencies correlated with hemizygous MAGOH loss. Mutual information metric 
(RNMI) is plotted against FDR for gene dependencies positively correlated with MAGOH 
deletion.
(d) Frequency of hemizygous MAGOH deletion across TCGA cohorts. Total frequency of 
MAGOH loss is indicated by a light blue bar; frequency of MAGOH loss occurring as a 
result of chromosome 1p deletion is indicated by a dark blue bar. Top panel shows total 
number of arm level copy number events in each tumor type.
(e) Cell viability in cell lines with (left) and without (right) hemizygous MAGOH loss upon 
MAGOHB suppression using a doxycycline-inducible shRNA against MAGOHB. Error bars 
show mean +/− s.d., n=3 replicates from a representative experiment repeated at least twice 
in each cell line; p-value by two-tailed, two-sample t-test.
(f) Colony formation in cell lines with (H1437, H460) or without (H1373) hemizygous 
MAGOH loss upon MAGOHB suppression using a doxycycline-inducible shRNA against 
MAGOHB. Photographs show representative wells from an experiment conducted in 
triplicate (quantification in Supplementary Figure 4); experiment was repeated at least twice 
in each cell line
(g) Cell viability measured upon MAGOHB knockdown in ChagoK1 cells with or without 
reconstitution of MAGOH-V5. Error bars show mean +/− s.d., n=5 replicates from a 
representative experiment repeated at least twice; p-value by two-tailed, two-sample t-test
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Figure 2. RNA splicing is globally altered upon MAGOHB suppression in cells with MAGOH 
loss, leading to the upregulation of NMD substrates.
(a) Differentially expressed transcripts in ChagoK1 cells (left) and in MAGOH-reconstituted 
ChagoK1 cells upon MAGOHB knockdown (right). Transcripts annotated as NMD 
substrates shown in red. Significance determined by a Wald test and adjusted for multiple 
comparisons using the Benjamini-Hochberg FDR. n=3 replicates were used in all conditions.
(b) Density distribution of proportional expression levels among coding isoforms 
corresponding to genes whose NMD isoforms are upregulated upon MAGOHB knockdown 
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in ChagoK1 cells (left) or MAGOH-reconstituted ChagoK1 cells (right). X-axis shows 
expression level of coding isoform(s) proportional to all expressed transcripts for a given 
gene; Y-axis shows density.
(c) Global changes in patterns of splice site usage upon MAGOHB knockdown in ChagoK1 
cells (left) or MAGOH-V5 reconstituted ChagoK1 cells (right). Splice event classes are 
shown in the schematic; solid lines denote “inclusion” event and dotted lines denote the 
alternative event for each class. Bar graphs denote the proportion of significant differentially 
spliced events that show greater inclusion in either the absence (red) or presence (blue) of 
MAGOHB knockdown in either ChagoK1 cells (left) or MAGOH-V5 reconstituted 
ChagoK1 cells (right).
(d) Significantly enriched Gene Ontology classes for genes (n=17) that show upregulation of 
NMD isoform(s) and concomitant downregulation of coding isoform(s). Significance was 
determined by a binomial test and adjusted for multiple comparisons using the Bonferroni 
correction.
(e) left) Sashimi plots around an activated exon within the 3’UTR of the HNRNPDL gene 
(inclusion of which creates an NMD-substrate transcript) in either the absence or presence of 
MAGOHB knockdown in either ChagoK1 cells or MAGOH-V5 reconstituted ChagoK1 
cells. Numbers reflect junction spanning reads averaged over three replicates for each 
condition.
right, top) Left panel, Transcript abundances for various isoforms of the HNRNPDL gene in 
either the absence (grey) or presence (red) of MAGOHB knockdown in either ChagoK1 
cells or MAGOH-V5 reconstituted ChagoK1 cells. Right panel, isoform abundances 
grouped by predicted coding protein length in each condition.
right, bottom) Western blot showing increased HNRNPDL protein levels upon MAGOHB 
knockdown in ChagoK1 cells but not MAGOH-V5 reconstituted ChagoK1 cells. 
Representative of a similar experiment repeated three times.
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Figure 3. IPO13 dependency is correlated with MAGOH and MAGOHB dependencies and is 
rescued by MAGOH reconstitution.
(a) Plot of gene dependencies (n=6300) correlated to MAGOH dependency vs. those 
correlated to MAGOHB dependency. Axes reflect Z-scored Pearson correlation of each 
dependency to either MAGOH dependency (X-axis) or MAGOHB dependency (Y-axis). 
MAGOH and MAGOHB self-correlations are not shown.
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(b) Heatmap of IPO13 dependency scores across 243 screened cell lines. Black bars denote 
cell lines that share dependency on IPO13 and either MAGOH,MAGOHB, or both (1); cell 
lines that carry a hemizygous deletion in MAGOH (2); IPO13 (3); MAGOHB (4).
(c) Cell viability measured upon shRNA-mediated IPO13 knockdown in cell line without 
(HCC1359, left) and with (H1437, right) MAGOH loss. Error bars show mean +/− s.d, n=4 
replicates per cell line; p-value by two-tailed, two-sample t-test.
(d) Colony formation in MAGOH-deleted H460 cells upon IPO13 knockdown in either the 
absence (top) or presence (bottom) of MAGOH-V5 reconstitution. Photographs show 
representative wells from an experiment conducted in triplicate (quantification in 
Supplementary Figure 11); experiment was repeated three times.
(e) Fold change in expression of the NMD substrates SC1.6 and SC1.7 of the SRSF2 gene in 
H460 cells upon IPO13 knockdown (IPO13-sh2) in either the presence (red) or absence 
(blue) of MAGOH-V5 reconstitution. Data normalized to expression in the shGFP condition. 
Error bars show mean +/− s.d., n=3 technical replicates per condition.
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Figure 4. MAGOHB and IPO13 are in vivo dependencies in MAGOH-deleted xenografts.
(a,b) Schematic (a) and growth curves (b) of H1437 xenografts in nude mice upon 
MAGOHB suppression. H1437 cells were transduced with lentivirus expressing a 
doxycycline-inducible shRNA against MAGOHB and injected into the flanks of nude mice. 
Once palpable tumors had formed (7d), mice were randomized to either normal chow or 
chow supplemented with doxycycline. Tumor volume over time is plotted in each arm. Lines 
show mean +/− s.e.m for n=6 tumors per arm. p-values listed for significant (<0.05) time 
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points by two-tailed, two-sample t-test; p also < 0.0001 by two-way ANOVA between +Dox 
and –Dox curves.
(c) Surface expression for NRP-1 and αVβ3 (co-receptors for iRGD-containing 
nanocomplexes) in H1437 cells, as assessed by flow cytometry. Repeated twice with similar 
results.
(d,e) Schematic (d) and growth curves (e) of H1437 xenografts in nude mice upon 
MAGOHB or IPO13 suppression using an siRNA-carrying tumor-penetrating nanocomplex 
(TPNC). Following palpable tumor formation, mice received intra-tumoral injections of 
TPNC containing either siRNA against GFP (control) MAGOHB, or IPO13. Lines show 
mean +/− s.e.m. for n=10 tumors per arm; p-value by two-way ANOVA.
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